Significance of CXCR3 expression in gastric low‐grade B‐cell lymphoma of mucosa‐associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication

Gastric mucosa‐associated lymphoid tissue (MALT) lymphoma is a distinct low‐grade lymphoma that often regresses upon Helicobacter pylori eradication. It was reported that the chemokine receptor CXCR3 is expressed not only on activated T cells, but also on MALT lymphoma cells, and that CXCR3‐positive...

Full description

Saved in:
Bibliographic Details
Published inCancer science Vol. 99; no. 9; pp. 1769 - 1773
Main Authors Yamamoto, Hideko, Nakamura, Tsuneya, Matsuo, Keitaro, Tajika, Masahiro, Kawai, Hiroki, Ohmiya, Naoki, Niwa, Yasumasa, Goto, Hidemi, Nakamura, Shigeo
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.09.2008
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gastric mucosa‐associated lymphoid tissue (MALT) lymphoma is a distinct low‐grade lymphoma that often regresses upon Helicobacter pylori eradication. It was reported that the chemokine receptor CXCR3 is expressed not only on activated T cells, but also on MALT lymphoma cells, and that CXCR3‐positive B lymphocytes migrate or home to the MALT of MALT lymphoma. In the present study, we aimed to elucidate the correlation between CXCR3 expression and the clinicopathological features of gastric MALT lymphoma, and to determine whether CXCR3 expression was predictive of responsiveness to H. pylori eradication. Sixty‐seven patients with gastric MALT lymphoma in a single‐center study were treated with H. pylori eradication therapy. We evaluated the correlation of CXCR3 expression with response to H. pylori eradication therapy by logistic regression stratified according to potential confounders. Immunohistochemical analysis revealed that 28 of 67 cases (42%) were positive for CXCR3 expression. CXCR3 expression was significantly more prevalent in those without H. pylori infection, advanced‐stage disease, and in those with API2–MALT1 fusion. In overall analysis, those with CXCR3 expression showed a significantly increased risk of non‐responsiveness to H. pylori eradication therapy (odds ratio = 28.6; 95% confidence interval 5.70–143.4) compared to those without CXCR3 expression. This higher risk was observed consistently regardless of sex, API2–MALT1 fusion, H. pylori infection, or clinical stage. We showed that CXCR3 expression was an independent predictive factor for non‐responsiveness to H. pylori eradication therapy in patients with gastric MALT lymphoma. (Cancer Sci 2008; 99: 1769–1773)
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/j.1349-7006.2008.00883.x